Margarita Majem
Universitat Autònoma de Barcelona(ES)Hospital de Sant Pau(ES)Sociedad Española de Medicina Interna(ES)Biomedical Research Institute(US)Institut Català de la Salut(ES)Spanish Ovarian Cancer Research Group(ES)Institut de Recerca Sant Pau(ES)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Cancer Immunotherapy and Biomarkers, Lung Cancer Diagnosis and Treatment, Cancer Genomics and Diagnostics
Most-Cited Works
- → Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial(2015)6,477 cited
- → Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer(2009)2,363 cited
- → Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer(2020)1,691 cited
- → Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer(2023)939 cited
- → Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial(2020)798 cited
- → Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study(2016)636 cited